Elea Phoenix is a top Argentinean Laboratory that has been researching and developing trustworthy and innovative medicines for a wide range of medical specialities since 1939. With leading trademarks, research and development projects of our own and licences from International renowed Companies. With Industrial Manufacturing Plants that operate efficiently, a wide distribution network, we focus firmly on the development of new products, in the following areas: Oncology, Biotechnology, Cardiology, Neuropsychiatry, Woman`s Health. Laboratorio ELEA is currently working with monoclonal antibodies, recombinant proteins, synthetic peptides, therapeutic vaccines for oncology. We are the first Company to launch a monoclonal antibody in 1997 , and in 2014 we launched the first Biosimilar mAb for Rituximab and Bevacizumab in 2016 . Now with have a potfolio of over 600 products, ranking 2nd for OTC/RX products. We have a strong portfolio in Biotech, launching Biopharmaceutical products every 2 years. | Elea is a top Argentinean Laboratory that has been researching and developing trustworthy and innovative medicines for a wide range of medical specialities since 1939. With leading trademarks, research and development projects of our own and licences from International renowed Companies. With Industrial Manufacturing Plants in Argentina and Latam that operate efficiently, a wide distribution network in several countries, we focus firmly on the development of new products, in the following areas: Oncology, Biotechnology, Cardiology, Neuropsychiatry, Woman`s Health. Laboratorio ELEA is currently working with monoclonal antibodies, recombinant proteins, synthetic peptides, therapeutic vaccines for oncology. We are the first Company to launch a monoclonal antibody in 1997 , and in 2014 we launched the first Biosimilar mAb for Rituximab and Bevacizumab in 2016 . Now with have a potfolio of over 600 products, ranking 2nd for OTC/RX products. We have a strong portfolio in Biotech, launching Biopharmaceutical products every 2 years. | We are an Argentine pharmaceutical company with more than 80 years of experience, dedicated to the research, development, and manufacturing of quality medicines for various medical specialties. Since 1939, we have stood out for offering innovative solutions that improve the health and quality of life of people, both in Argentina and throughout Latin America. ✅ We integrate our own research and development, alliances with important international laboratories and high-tech production plants, ensuring that innovation is present in every stage of our process. All this, together with an extensive distribution network, positions us among the leaders in the Argentine pharmaceutical market. Our main therapeutic areas are: Women’s Health – Urology – Anti-infectives – Respiratory – Internal Medicine – Ophthalmology – Neurosciences – Cardiometabolism – Osteoarticular – Gastroenterology – Oncology and Biotechnology – HIV – Over-the-Counter. We have a strong portfolio of Biopharmaceutical products in the market (EPO, Rituximab, Bevacizumab, Trastuzumab, Adalimumab, Pembrolizumab, Racotumomab, Nimotuzumab).
K Pharma Inc.
K Pharma emerged as a spin-off company from Keio University School of Medicine, dedicated to transforming pioneering research by Professor Hideyuki Okano (Department of Physiology) and Professor Masaya Nakamura (Department of Orthopaedic Surgery) into practical applications. Our unwavering commitment to pushing the boundaries of healthcare has led us to specialize in medical treatments involving nerve regeneration and iPS drug discovery. We pride ourselves on maintaining a close partnership with Keio University School of Medicine, with recent strides in iPS drug discovery culminating in the successful completion of the first phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) treatment. With the phase 3 study looming, we are excited to continue our exploration of iPS drug discovery to tackle other intractable neurological diseases. Our collaboration extends to regenerative medicine, where we are currently in preparing sponsor-initiated clinical trials for the treatment of subacute spinal cord injury. Looking ahead, we plan to broaden the scope of regenerative medicine to encompass treatments for chronic spinal cord injury and cerebral infarctions. | K Pharma is a publicly traded company (TSE) that originated from Keio University School of Medicine and was established in November 2016. Leveraging human iPS cell technology discovered by Professor Shinya Yamanaka of Kyoto University in 2007, K Pharma is engaged in regenerative medicine business for conditions such as spinal cord injury and stroke, as well as “iPS drug discovery” business targeting intractable neurological disorders. K Pharma is committed to addressing unmet medical needs worldwide and contribution.
JSS Medical Research
JSS Medical Research Inc., is a full-service clinical research organization (CRO) with strong academic affiliations that was founded in the mid-1980s by Dr. John S. Sampalis, CEO/CSO, a tenured Professor in the Faculty of Medicine of McGill University and the University of Montreal. All senior scientific members of JSS Medical Research have training in clinical research and epidemiology, and are affiliated with McGill University, University of Montreal or Laval University. Through our corporate head office, located in Montreal, Canada, regional hubs in Bogotá (Colombia) and New Delhi (India), and our global network of partners, JSS has successfully conducted over 1100+ multi-therapeutic clinical studies in 58 countries in the last 10 years. we can conduct clinical research in North America, Latin America, Europe, the Middle East and Asia. The services offered by JSS Medical Research cover the entire spectrum of clinical research from study conception, design, execution, data analysis and dissemination of results. The staff of JSS Medical Research includes clinical epidemiologists, physicians, biostatisticians, project managers, quality assurance experts, monitors, medical writers and information technology experts. One of our distinguishing attributes is our methodological knowledge and expertise in the design and execution of clinical studies. Globally, JSS Medical Research has conducted over 1200 projects. Specifically, within the Americas (mainly USA and Canada), 522 were completed with • 26 Phase I trials, • 92 Phase II, • 119 Phase III trials, • 263 were Phaser IV – Post-Marketing Observational Studies or Health Economic and Outcome Research projects, • 27 Medical device Studies, and • 18 Ministry of Health Regulatory Submissions in the LATAM Region. The therapeutic areas covered in these projects include – but are not limited to –autoimmune disorders, cardiovascular disease, CNS/psychiatric conditions, dermatology, endocrinology (diabetes), gastroenterology, infectious diseases (including COVID/HIV/hepatitis), medical devices, pain management and trauma, obesity, oncology/hematology, ophthalmological diseases, respiratory conditions, rheumatology (arthritis/OA), transplantation, women’s health and vaccines. www.JSSresearch.com
Inventage Lab Inc
.. | Inventage Lab(KOSDAQ: 389470) is a clinical-stage biopharmaceutical company specializing in drug delivery system, especially the development of long-acting injectables and lipid nanoparticles using a microfluidic manufacturing platform. IVL-DrugFluidic® platform enables the production of high-quality of microsphere based long-acting injectable formulations by eliminating initial drug over-release and ensuring the mass production of uniform microspheres. It has been successfully applied to veterinary medicine and clinical trials for androgenic alopecia, dementia, and addiction treatments. The platform also supports drug re-discovery and partnerships for novel drug formulations with partnering pharmaceutical companies. Harnessing our HANDYGENE™ system, this platform focuses on developing lipid nanoparticles (LNPs) for vaccines and gene therapies. Inventage Lab also offers services, including LNP formulation and non-clinical and clinical sample production, while diversifying its business through selling and subscribing to its LNP manufacturing equipment.
IBEX Therapeutics SA
Ibex Therapeutics is Swiss biotech company developing a patented oral topical therapy to cure and prevent oral mucositis and oral candidiasis, debilitating conditions which very often occur as adverse effect of cancer chemo- and radiotherapy and affects the care journey and the quality of life of cancer patients. A de-risked and short path to registration and commercialization by 2028, as validated by the German health authority BfArM: the lead product (containing 2 water-based plant extracts) is produced in GMP conditions and has confirmed its efficacy and safety in a pilot study in cancer patients. Ibex Tx is raising CHF 3 million, of which 1.0+ million has already received soft commitments, with the largest part of the proceeds to fund a final pivotal clinical study, and some portfolio extensions (including a probiotic to synergize with the oral topical therapy, and a spray presentation to augment portability and convenience of use by ambulatory patients). Strong market fundamentals: sustained medical need (increasing incidence of cancer and use of mucositis-inducing therapies), and absence of reference treatment. Further, Ibex Tx will register the product in several geographies (EU, USA, Asia, BRICS), and sign licensing agreements to ensure efficient commercialization outside of Switzerland.
Hypera Pharma
A giant in the brazilian market, Hypera Pharma is the largest brazilian pharmaceutical company, owner of a strong portfolio of non-replicable leading brands in Brazil including 21 power brands. Hypera is looking for strategic players to partner in improving our portfolio with novel pharma and innovative technologies. | Hypera Pharma is one of the biggest and most diversified pharmaceutical companies in Brazil. It’s present in all relevant segments of the retail pharmaceutical sector in Brazil, with leadership in several product categories. The company offers high-quality products, and keeps investing in innovation to grow in a sustainable way. The strength of the Company in the pharmaceutical market is supported by a large-scale and low-cost operation based in the largest pharmaceutical operating complex in Latin America, located in Anápolis, Goiás. It is a 120,000-square meter structure with more than 9,000 employees. Annually it produces more than 650 million solid doses, 20 million units of injectable drugs and eye drops, more than 250 million units of vitamins and 300 million units of liquids, creams, oils and lotions. To support constant innovation in its business, the Company created in 2017 Hynova, the most modern pharmaceutical research center in Brazil, which houses a team of highly qualified professionals, masters and doctors for the development of medicines, dermocosmetics and nutraceuticals, using cutting-edge technology to be a pioneer in Brazil. The Company also has a broad national sales and distribution structure. Its products are distributed throughout Brazil, directly to retailers, or indirectly through distributors and wholesalers. Founded in 2001 as Hypermarcas, its corporate name changed in 2017 to Hypera Pharma, evidencing the Company’s new focus in the pharmaceutical market. It is listed in B3’s Novo Mercado since 2008 and currently employs around 10,000 people.
HoHo Biotech Co., LTD
HOHO Biotech is a Taiwan-based biotech company specializing in molecular hydrogen therapy as a clinically proven adjuvant for managing Autoimmune diseases, chronic Inflammation, and Cancer. Its flagship products include hydrogen capsules and H₂/O₂ inhalation devices, used in hospitals, clinics, and pharmacies. Backed by clinical trials and publications, HOHO Biotech offers a natural antioxidant and anti-inflammatory capsule that enhances drug efficacy and reduces side effects. Partnering with major medical centers, HOHO Biotech leads the field in hydrogen medicine, aiming for global expansion through research, regulatory approval, and partnerships. Search “HOHO Biotech hydrogen therapy” or visit www.hoholab.com.tw to learn more. HOHO Biotech LinkedIn: www.linkedin.com/company/hoho-biotech Benson LinkedIn: https://www.linkedin.com/in/kuang-yih-wang-ab14b621/ https://www.hohobio.com Website Taiwan: https://www.hoholab.com.tw/ Phone: +886920757313 Email: Benson@hohobio.com Industry Hospitals and Health Care Company size 2-10 employees 2 associated members LinkedIn members who’ve listed HOHO Biotech as their current workplace on their profile. Founded 1976 Specialties molecular hydrogen therapy, hydrogen capsules, anti-inflammatory capsule, autoimmune disease adjuvant, natural antioxidant supplement, hydrogen medicine Taiwan, H₂/O₂ inhalation device, clinical trial hydrogen therapy, reduce drug side effects, and HOHO Biotech Taiwan HoHo Biotech was founded in 2017. The company focuses on Autoimmune Disease, Hydrogen-Based Molecular Medicine, and gut microenvironment research. In 2018, it developed a “Hydrogen Capsule”, a proprietary natural coral calcium material. In 2020, it received TFDA approval, becoming a “Prescription use in Regional Hospital”, based on clinical trial data. In 2022, it became a “Prescription Use in Medical Center”. In 2024, Launched H2 Capsule in “Pharmacy Chains”, more than 200 shops. In 2024, HoHo introduced an AI molecular simulation system and built the Molecular Intelligence Engine, combining functional material science with computational modeling. In 2025, published more than 18+ Medical Papers as evidence of the “Hydrogen Capsule” as a perfect “Adjuvant” in the Autoimmune area. Launched HydroChat, an AI assistant for personalized applications. This development led to the company’s core strategy, Gut Engineering, which uses molecular signals to regulate the intestinal environment.
HKUBio – Hong Kong Universal Biologicals Company Limited
Hong Kong Universal Biologicals Company Limited (HKUBio) is a Hong Kong -based biotech R&D Company, spinoff from The University of Hong Kong (HKU), Centre for Virology, Vaccinology and Therapeutics (CVVT) (InnoHK@HKUMed), and in collaboration with The State Key Laboratory for Emerging Infectious Diseases (SKLEID) of the Department of Microbiology at the University of Hong Kong. We set up at the Hong Kong Science Park in developing innovative vaccine products, possesses the Viral Vector Vaccines Technology system (DelNS1), along with a series of patents for developing intranasal vaccines for respiratory viruses. This technology platform is based on a flu-based viral vector and can be utilized for creating vaccines for flu, COVID-19, and other respiratory viral diseases. The first intranasal spray vaccine for COVID-19 developed using this technology platform has been approved for human use in mainland China in 2022. One of the unique advantages of this vaccine system is its ability to combine vaccines for flu and other respiratory viral infections, inducing both systemic and mucosal immunity, a feat not achievable by other intramuscularly injected vaccines. This platform technology was awarded the Gold Medal with Congratulations of the Jury” the Special Edition 2021 Inventions Geneva Evaluation Days The platform of the DelNS1 vaccine system technology has been utilized to generate vaccines for seasonal influenza, COVID-19, Flu-COVID (a combination vaccine for flu and COVID-19 in a single composition), Flu-RSV (a combination vaccine for flu and RSV in a single composition), and Flu-hMPV (a combination vaccine for flu and hMPV in a single composition). Our showcase will highlight the technology and the development of vaccine candidates for a variety of common cold viruses. The DelNS1-RBD vaccine for COVID-19 based on this technology has successfully completed all phases of clinical trials and has received approval for human use in China in 2022. Development is underway for vaccines targeting influenza and RSV, with plans to enter investigational new drug (IND) status within one to two years. Additionally, a vaccine candidate for the potential emerging H5N1 virus has been created and will undergo evaluation in humans to facilitate technology stockpiling for pandemic preparedness. Concurrently, a series of vaccines for common cold viruses are in development and are slated for human evaluation within the next 3-5 years through collaborative efforts with other partners. This technology focuses on Life and Health Technology R&D. Given the impact of the COVID-19 pandemic and the efficient transmission of SARS-CoV-2, The development of effective vaccines that can induce both systemic and mucosal immunity is considered to be the focus of the next generation of vaccines for respiratory viruses. The technology showcased here is exceptionally innovative as it can be integrated with flu vaccines to target other respiratory viral infections. Its practicality is underscored by successful human trials and the approval of a product based on this technology for human use.
Hemispherian AS
At Hemispherian, we are developing a novel type of cancer therapeutics targeting the DNA damage response. Our drugs are small-molecule TET2 agonists that leverage a preexisting condition in cancer. With GLIX1 as a monotherapy, we initially want to target Glioblastoma as a first indication. GLIX1 has all the properties needed to succeed in this indication. It is a small molecule that readily passes the BBB; it has excellent efficacy and excellent tolerability. Additionally, we can use GLIX1 to sensitize HR-proficient cancers to PARP inhibitors. This substantially expands the market size for both GLIX1 and already approved PARP inhibitors. We have a complete preclinical package and have already produced the GMP DP for clinical development. We will file our IND in May this year and subsequently run a Phase I/IIa study in the US. For this, we have the support of leading clinicians from Northwestern, Stanford, and Mount Sinai. We are looking to raise USD 20M for the clinical development of GLIX1. We already have commitments from the EIC Fund and from existing investors.
Health Ever Bio-Tech Co., Ltd.
Health Ever Bio-Tech Co., Ltd. (HEB) was established to focus on the research and development of innovative botanical drugs backed with scientific and medical evidences for today’s great unmet medical needs. With in-house ISO/IEC 17025 certified laboratory and PIC/S GMP manufacturing facility, HEB has been actively involved in the preclinical and clinical development of botanical new drugs that have been verified effective and safe on animal, cellular and human studies. HEB has built a network of domestic and international scientific advisors and consultants who are top-notch in the industry to maximize the success and quality of our pipeline. HEB endeavors to provide botanical new drugs of the best quality and makes strenuous efforts to improve the health of our compatriots. | Health Ever Bio-Tech Co., Ltd. (HEB) was established to focus on the research and development of innovative new drugs backed with scientific and medical evidences for today’s great unmet medical needs. With in-house ISO/IEC 17025 certified laboratory and PIC/S GMP manufacturing facility, HEB has been actively involved in the preclinical and clinical development of innovative new drugs that have been verified effective and safe on animal, cellular and human studies. HEB has built a network of domestic and international scientific advisors and consultants who are top-notch in the industry to maximize the success and quality of our pipeline. HEB endeavors to provide innovative new drugs of the best quality and makes strenuous efforts to improve the health of our compatriots.